PharmaTher Launches M3DICINES National Network Program to Provide 3D-Printed Medicines for Rare Diseases, Discontinued Medicines, Drug Shortages and National Emergencies
PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINES
PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake Pharmaceutical 3D Printing Platform
PharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for Its Personalized Medicine and Peptide Platform, PERSONALIZ3D
PharmaTher Establishes PERSONALIZ3D to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D Printing
PharmaTher Collaborates with Craft Health to Evaluate CraftMake GMP-Ready Pharmaceutical 3D Printing Platform for Personalized Peptides
PharmaTher Launches Personaliz3D Peptides to Advance Personalized Peptide Care Following Positive FDA Advisory Committee Recommendations
PharmaTher Enters into Collaboration Agreement for KetaMist to Advance Needle-Free Ketamine Treatment Toward FDA Approval
PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness
PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides
PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery
Angkor Resources Reports University Study Supporting Copper-Molybdenum Porphyry Potential at Andong Bor, Cambodia
VanadiumCorp and Université de Sherbrooke Announce Publication of Peer-Reviewed Research on Lac Doré Vanadiferous Titanomagnetite
